New blood thinner better at preventing recurrent blood clots than aspirin

March 19, 2017
An international study of 3,396 patients with venous thromboembolism in 31 countries shows that the blood thinner rivaroxaban is just as safe as aspirin and more effective at preventing blood clots. Credit: The Ottawa Hospital

An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study published in the New England Journal of Medicine.

At least one out of 1,000 Canadians will experience one of these every year, a condition called venous thromboembolism. The clots can be deadly if they travel to the lungs (pulmonary embolism), and are the third most common cardiovascular cause of death after heart attack and stroke.

Venous thromboembolism is a chronic disease, with risks of additional blood clots over a patient's lifetime. However, many physicians and are deciding against long-term treatment with blood thinners because of concern about the risk of bleeding. Some are choosing aspirin instead because they consider it to be safer.

The large international study of 3,396 patients with venous thromboembolism in 31 countries shows, however, that rivaroxaban is more effective than aspirin.

"Not only that, but in testing two doses of rivaroxaban, we found that we have the option of lowering the daily dose for extended treatment," said Dr. Jeffrey Weitz, principal investigator of the study and professor of medicine and biochemistry and biomedical sciences at the Michael G. DeGroote School of Medicine at McMaster University. "This will ease the long-term concerns of both patients and their doctors."

During the study from March 2014 to March 2016, patients received either a daily 20mg dose of rivaroxaban, a 10mg dose of rivaroxaban, or a 100 mg dose of aspirin. They took these medications for up to 12 months after they had received treatment for their initial clot.

The researchers found that patients taking aspirin had the highest rate of recurrent blood clots, at 4.4 percent. The rates of recurrent clots for patients taking 20mg and 10mg of rivaroxaban were significantly lower, at 1.5 and 1.2 percent respectively.

When they looked at bleeding side-effects, there were no statistically significant differences between the treatments. The rates of major bleeding were 0.3 percent in the group taking aspirin, and 0.5 percent and a 0.4 percent in the groups taking 20 mg and 10mg of rivaroxaban, respectively.

Dr. Philip Wells, head of the Department of Medicine and senior scientist at The Ottawa Hospital and the University of Ottawa and an author of the study, will present the research at the American College of Cardiology's 66th Annual Scientific Session today.

"We know from previous studies that only about 40 percent of patients are actually on long-term ," said Wells.

"We hope that this study, which shows the blood thinner rivaroxaban, is as safe as but much more effective at preventing future clots, will convince patients and their physicians to continue life-long medication that can prevent potentially dangerous blood clots."

Rivaroxaban is a prescription drug available in Canada for about $100 a month, and most private insurance plans will cover the cost. Aspirin costs pennies a day and is available over the counter.

Explore further: Lower inpatient costs for dabigatran, rivaroxaban in A-fib

Related Stories

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

January 17, 2017
(HealthDay)—For patients with newly diagnosed atrial fibrillation (AF), inpatient costs are lower with dabigatran and rivaroxaban than with warfarin, according to a letter published online in the Jan. 24 issue of the Journal ...

Aspirin cuts risk of clots, DVT by a third, new study finds

August 25, 2014
Low dose aspirin lowers the occurrence of new venous blood clots – and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new ...

Study reports progress in preventing bleeding in atrial fibrillation

November 14, 2016
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures ...

Aspirin may prevent recurrence of deep vein blood clots

May 23, 2012
(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, according to ...

Stroke risk high when anti-clotting drugs stopped

April 25, 2012
Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Aspirin a viable treatment for recurrent, serious blood clots, study shows

November 5, 2012
(Medical Xpress)—Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot, a new study shows.

Recommended for you

Research suggests new pathways for hyperaldosteronism

December 7, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with researchers at Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

Clot-busting drugs not recommended for most patients with blood clots

December 6, 2017
Not all patients with blood clots in their legs - a condition known as deep vein thrombosis - need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.

Mitochondrial protein in cardiac muscle cells linked to heart failure, study finds

December 5, 2017
Reducing a protein found in the mitochondria of cardiac muscle cells initiates cardiac dysfunction and heart failure, a finding that could provide insight for new treatments for cardiovascular diseases, a study led by Georgia ...

Blood pressure declines 14 to 18 years before death

December 4, 2017
Blood pressure in the elderly gradually begins to decrease about 14 or so years before death, according to a new study published today in the JAMA Internal Medicine.

Study links common male medical condition and vascular disease

December 1, 2017
Men who suffer symptoms from varicoceles, enlarged veins in the scrotum, are more likely to develop vascular disease and metabolic disease, such as diabetes, according to a study by Stanford University School of Medicine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.